Global Hodgkin Lymphoma Treatment Market Size (2024 - 2029)

The Hodgkin lymphoma treatment market is anticipated to experience significant growth, driven by the increasing need for treatment due to patients' vulnerability to infections like SARS-CoV-2, which is exacerbated by their immunosuppressive therapies. The market's expansion is further supported by improved access to treatments and heightened awareness of Hodgkin lymphoma, particularly among older patients and those with relapsed or refractory cases. Ongoing research and development, including the approval of new therapies for pediatric patients, are also contributing to market growth. However, the market's expansion may be hindered by the high cost of treatment and potential long-term side effects.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Oncology Drugs Research Global Hodgkin Lymphoma Treatment Market Market Size

Market Size of Global Hodgkin Lymphoma Treatment Industry

Hodgkin Lymphoma Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 12.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Hodgkin Lymphoma Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Hodgkins Lymphoma Treatment Market Analysis

The Hodgkin lymphoma (HL) treatment market is expected to register a CAGR of 12.5% during the forecast period.

Patients with Hodgkin lymphoma are at a higher risk for SARS-CoV-2 infection as they typically receive immunosuppressive and chemotherapy drugs during treatment. For instance, in November 2021, a research study published by the Baishideng Publishing Group Inc. stated that patients with lymphoma appeared particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Furthermore, according to the same source, there is an increased risk of COVID-19-related serious events (ICU admission, mechanical ventilation support, or death) in patients with lymphomas as compared to COVID-19 patients without cancer and confirms the high vulnerability of such patients in the current pandemic. Hence, with the vulnerability of Hodgkin lymphoma to COVID-19, the need for its treatment has increased, driving the growth of the market. Additionally, there is better access to treatment as compared to the initial pandemic phase due to the lockdown, the market has reached its pre-pandemic level growth and is expected to grow significantly over the forecast period.

The growing burden of Hodgkin lymphoma as well as increasing awareness about it and high unmet needs in older patients and patients with relapsed or refractory (R/R) HL are key factors expected to drive the market over the forecast period. For instance, according to a CDC update in September 2022, the estimated 5-year limited duration prevalence counts for Hodgkin Lymphoma, is 38,289 out of which 17,437 are female and 20,851 are male. Various research studies on the efficacy of better treatments have been conducted. For instance, in June 2022, a research study published by the Journal of Clinical Oncology stated that the anti-CD30 antibody-drug conjugate, Brentuximab vedotin (Bv) is approved for adults with advanced-stage HL but its use has not been established in children or adolescents. Brentuximab vedotin with AVE-PC in a dose-intensive regimen has superior efficacy to ABVE-PC for pediatric patients with high-risk HL. A 59% risk reduction in EFS was achieved with no increase in toxicity. Such development is expected to drive the growth of the market over the forecast period.

Several biopharmaceutical companies are seeking approval for the advancement of Hodgkin lymphoma to improve the treatment which is expected to drive the market growth over the forecast period. For instance, in November 2022, the FDA approved brentuximab vedotin (Adcetris, Seagen, Inc.) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients two years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for brentuximab vedotin.

Hence, various ongoing studies on HL to provide better treatment options and product approval is contributing to the overall market growth. However, adverse long-term side effects and the high cost of treatment are expected to restrain the growth of the Hodgkin lymphoma treatment market.

Hodgkins Lymphoma Treatment Industry Segmentation

As per the scope of the report, Hodgkin's lymphoma (HL) is a type of lymphoma in which cancer originates from lymphocytes. Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is part of the body's germ-fighting immune system. In Hodgkin's lymphoma, white blood cells called lymphocytes grow out of control, causing swollen lymph nodes and growth throughout the body. 

The Hodgkin Lymphoma Treatment Market is Segmented by Treatment Type (Chemotherapy, Radiotherapy, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
Chemotherapy
Radiotherapy
Other Treatment Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Hodgkin Lymphoma Treatment Market Size Summary

The Hodgkin lymphoma treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the heightened awareness of its treatment options. The market is experiencing a resurgence as access to treatment improves post-pandemic, with ongoing research and clinical trials contributing to the development of more effective therapies. The vulnerability of Hodgkin lymphoma patients to infections like SARS-CoV-2 has underscored the importance of timely and effective treatment, further propelling market expansion. Key factors such as the high unmet medical needs in older patients and those with relapsed or refractory Hodgkin lymphoma are also expected to drive market growth. The approval of new therapies, such as brentuximab vedotin for pediatric patients, highlights the ongoing advancements in treatment options, which are anticipated to enhance market dynamics over the forecast period.

The market landscape is characterized by the presence of both global and regional players, with companies like Bristol-Myers Squibb, Merck & Co., and Seagen Inc. holding significant market shares. The competitive environment is further intensified by partnerships and collaborations aimed at advancing treatment technologies, such as the DRIVE-MRT solution for molecular radiotherapy. North America is expected to maintain a strong market position due to the rising incidence of Hodgkin lymphoma and the presence of developed healthcare infrastructure. Despite the promising growth prospects, challenges such as the high cost of treatment and potential long-term side effects may pose constraints. Nonetheless, the combination of innovative therapies, strategic partnerships, and a robust pipeline of clinical trials is set to drive the Hodgkin lymphoma treatment market forward.

Explore More

Global Hodgkin Lymphoma Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Hodgkin Lymphoma

      2. 1.2.2 Increasing Awareness about Hodgkin Lymphoma

      3. 1.2.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) HL

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Long-term Side Effects of Hodgkin Lymphoma Treatment

      2. 1.3.2 High Cost of Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Treatment Type

      1. 2.1.1 Chemotherapy

      2. 2.1.2 Radiotherapy

      3. 2.1.3 Other Treatment Types

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Global Hodgkin Lymphoma Treatment Market Size FAQs

The Global Hodgkin Lymphoma Treatment Market is projected to register a CAGR of 12.5% during the forecast period (2024-2029)

Bristol-Myers Squibb Company, Merck & Co. Inc., Biogen Inc., Amneal Pharmaceuticals, Inc. and Seagen Inc. are the major companies operating in the Global Hodgkin Lymphoma Treatment Market.

Global Hodgkin Lymphoma Treatment Report Snapshots

Hodgkin Lymphoma Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)